Equitable Trust Co. Makes New $417,000 Investment in Henry Schein, Inc. (NASDAQ:HSIC)

Equitable Trust Co. purchased a new stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 6,030 shares of the company’s stock, valued at approximately $417,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Cromwell Holdings LLC grew its holdings in Henry Schein by 93.4% during the 3rd quarter. Cromwell Holdings LLC now owns 352 shares of the company’s stock worth $26,000 after acquiring an additional 170 shares in the last quarter. Versant Capital Management Inc lifted its position in shares of Henry Schein by 274.6% in the 4th quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock worth $32,000 after purchasing an additional 335 shares during the period. City State Bank bought a new position in shares of Henry Schein during the fourth quarter valued at approximately $55,000. Farther Finance Advisors LLC increased its holdings in Henry Schein by 58.9% during the third quarter. Farther Finance Advisors LLC now owns 933 shares of the company’s stock valued at $68,000 after buying an additional 346 shares during the period. Finally, Mather Group LLC. raised its stake in Henry Schein by 43.7% in the fourth quarter. Mather Group LLC. now owns 1,503 shares of the company’s stock worth $104,000 after buying an additional 457 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently commented on HSIC. Bank of America raised Henry Schein from an “underperform” rating to a “buy” rating and boosted their price target for the stock from $69.00 to $84.00 in a research report on Monday, January 6th. StockNews.com upgraded Henry Schein from a “sell” rating to a “hold” rating in a research note on Thursday, November 7th. Mizuho began coverage on shares of Henry Schein in a research report on Wednesday, December 4th. They set a “neutral” rating and a $75.00 price target for the company. Jefferies Financial Group lifted their price objective on shares of Henry Schein from $77.00 to $80.00 and gave the stock a “hold” rating in a research report on Thursday, January 23rd. Finally, Barrington Research increased their target price on shares of Henry Schein from $82.00 to $90.00 and gave the company an “outperform” rating in a research report on Thursday, January 30th. Seven equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Henry Schein currently has an average rating of “Moderate Buy” and a consensus target price of $80.10.

Henry Schein Trading Down 1.8 %

Shares of Henry Schein stock opened at $77.48 on Wednesday. The firm’s 50 day simple moving average is $73.80 and its two-hundred day simple moving average is $71.90. The firm has a market capitalization of $9.66 billion, a price-to-earnings ratio of 31.88, a PEG ratio of 2.21 and a beta of 0.91. Henry Schein, Inc. has a 12-month low of $63.67 and a 12-month high of $82.63. The company has a current ratio of 1.42, a quick ratio of 0.82 and a debt-to-equity ratio of 0.46.

Insider Activity

In related news, COO Michael S. Ettinger sold 12,240 shares of Henry Schein stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $75.00, for a total transaction of $918,000.00. Following the completion of the sale, the chief operating officer now owns 87,706 shares of the company’s stock, valued at $6,577,950. The trade was a 12.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 1.14% of the company’s stock.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.